Compare Medtronic PLC (MDT) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Shell PLC — how do they compare? Medtronic PLC trades at $82.52 (market cap $106.61B), while Shell PLC trades at $86.95 (market cap $235.24B). The key difference: Shell PLC is far larger — about 2.2× Medtronic PLC's market cap, and Shell PLC pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| MDT | SHEL | |
|---|---|---|
Market Cap | $106.61B | $235.24B |
Sector | Health | Energy |
52-Week High | $105.35 | $94.15 |
52-Week Low | $73.75 | $70.31 |
Enterprise Value | $125.36B | $287.77B |
Dividend Yield | 3.46% | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.
The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.
Shell (SHEL) trades at $86.20, down 1.28% on the day, with strong technical momentum as moving averages signal bullish sentiment. The company maintains solid fundamentals with a P/E of 13.6 and net income margin of 7.01%, though revenue has declined from $381.3B in 2022 to $266.9B in 2025. Recent developments include expansion in Caribbean LNG infrastructure and the pending $16.4B acquisition of ARC Resources, positioning for strategic growth despite Middle East production disruptions.
Outlook remains positive with analyst consensus at Buy (69%) and $114.13 price target, representing 32% upside. Key risks include geopolitical volatility affecting oil prices and ongoing production challenges. The stock offers value through discounted valuation metrics and dividend yield, though investors should monitor execution on growth initiatives and energy market stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
